ChromaDex price target raised to $6 from $4.25 at Roth MKM

Roth MKM raised the firm’s price target on ChromaDex to $6 from $4.25 and keeps a Buy rating on the shares. The stock has had a sharp rise in recent weeks but remans undervalued and does not give sufficient credit to the breadth of opportunities for growth of Tru Niagen, for development of additional products in adjacent markets, or for the potential of licensing and/or supply partnerships with pharmaceutical companies, the analyst tells investors in a research note.